Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alvotech - Ordinary Shares (NQ: ALVO ) 13.16 +0.39 (+3.09%) Streaming Delayed Price Updated: 9:46 AM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alvotech - Ordinary Shares < Previous 1 2 3 4 5 6 7 Next > Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) May 13, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 May 02, 2024 From Alvotech Via GlobeNewswire U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire ALVO Stock Earnings: Alvotech Reported Results for Q4 2023 March 20, 2024 Alvotech just reported results for the fourth quarter of 2023. Via InvestorPlace Alvotech's Earnings: A Preview March 19, 2024 Via Benzinga U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) April 30, 2024 From Alvotech Via GlobeNewswire Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) April 24, 2024 From Alvotech Via GlobeNewswire Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday April 19, 2024 Via Benzinga Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) April 19, 2024 From Alvotech Via GlobeNewswire Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) April 16, 2024 From Alvotech Via GlobeNewswire Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 April 03, 2024 From Alvotech Via GlobeNewswire Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday March 25, 2024 U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Via Benzinga Topics Stocks Exposures US Equities Alvotech Announces Increase in Number of Own Shares March 22, 2024 From Alvotech Via GlobeNewswire Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update March 20, 2024 From Alvotech Via GlobeNewswire Earnings Scheduled For March 20, 2024 March 20, 2024 Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million. Via Benzinga Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET March 05, 2024 Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024 From Alvotech Via GlobeNewswire Alvotech Appoints Interim Chief Quality Officer February 29, 2024 From Alvotech Via GlobeNewswire TEVA Stock Pops 4% as Teva Receives FDA Approval February 26, 2024 Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar. Via InvestorPlace Exposures Product Safety Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today? February 26, 2024 FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more. Via Benzinga Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share February 26, 2024 From Alvotech Via GlobeNewswire Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® February 23, 2024 From Alvotech Via GlobeNewswire Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® February 23, 2024 From Teva Pharmaceutical Industries Limited Via Business Wire Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) February 15, 2024 From Alvotech Via GlobeNewswire American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday January 29, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® January 29, 2024 From Alvotech Via GlobeNewswire 3 mid-caps under $20 that Wall Street loves January 23, 2024 MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates 12 Health Care Stocks Moving In Friday's Intraday Session January 19, 2024 Via Benzinga Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 January 19, 2024 From Alvotech Via GlobeNewswire STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara January 10, 2024 From Alvotech Via GlobeNewswire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
